Propylene glycol, a major electronic cigarette constituent, attenuates the adverse effects of high dose nicotine as measured by intracranial self-stimulation in rats

In response to the dramatic increase in the popularity of electronic cigarettes (ECs), the Food and Drug Administration Center for Tobacco Products (FDA CTP) recently extended its regulatory authority to these products (Backinger et al., 2016; Barraza et al., 2017; Chang et al., 2017; Cobb and Sonti, 2016; National Academy of Sciences, Engineering, and Medicine, 2018). Effective FDA regulation of ECs requires characterization of the pharmacological determinants of their abuse liability. While it is generally accepted that nicotine is the primary addictive constituent in tobacco products including ECs, other constituents (e.g., minor alkaloids) may also contribute to tobacco use by mimicking or altering the effects of nicotine (for review, see Brennan et al., 2014; Hoffman and Evans, 2013; LeSage et al., 2018).

Source: Drug and Alcohol Dependence - October 18, 2018 Category: Addiction Authors: Andrew C. Harris, Peter Muelken, Zach Haave, Yayi Swain, John R. Smethells, Mark G. LeSage Tags: Full length article Source Type: research